Glutamate for Metabolic Intervention in Coronary Surgery II
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
The aim of GLUTAMICS II is to evaluate whether intravenous glutamate infusion surgery reduces
the risk of postoperative heart failure as measured by plasma NT-proBNP in patients
undergoing moderate to high-risk coronary artery bypass graft surgery. Patients accepted for
coronary artery bypass surgery of at least two vessel disease or left main stenosis with or
without concomitant procedure and considered to be at moderate to high surgical risk
preoperatively with regard to postoperative heart failure will be studied. The primary
endpoint is postoperative increase of NT-proBNP from the day before surgery to the third
postoperative day.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Linkoeping
Collaborators:
Blekinge County Council Hospital Region Örebro County Sahlgrenska University Hospital, Sweden University Hospital, Umeå Uppsala University Hospital, Sweden